The report of this subcommittee concerns the impact of contact lenses (CLs) on the ocular surface, with a particular emphasis on CL discomfort (CLD). We define the ocular surface, its regional anatomy, and the physiological responses of each region to CL wear

Purpose: The aim of the study was to understand natural changes of meibomian glands (MG) that occur with aging in the absence of any ocular pathology or ocular discomfort symptoms, to differentiate between “age normal” and pathologic or dysfunctional changes of the MG. Methods: A total of 185 subjects (109 females) with no pre-existing ocular and systemic abnormalities were recruited and divided into four age groups: 25 to 34, 35 to 44, 45 to 54, and 55 to 66 years. At a single visit, the following MG measures were collected: meibum quality (MQ) and MG expressibility (MGE) of the lower lid, and MG drop-out score (meiboscale) using infrared meibography of the upper and lower lids. Assessments of anterior eye, tear function variables, noninvasive and invasive tear breakup time (TBUT), corneal integrity, and lid wiper epitheliopathy were also performed during the visit. An Ocular Surface Disease Index (OSDI) questionnaire was used to record dry eye symptoms. Meibum lipids samples were collected and analyzed. Results: A majority of the study population (61%) was asymptomatic. There was a significant worsening in the MQ (P < 0.048), MGE (P < 0.03), and meiboscale (P < 0.01) with increasing age. Significant increase was observed in anterior blepharitis (P < 0.001) and telangiectasia (P < 0.02) with aging. Interestingly, tear osmolarity decreased significantly (P < 0.001), while tear meniscus height (P < 0.001) and invasive TBUT (P = 0.02) increased with increase in age. There was no significant association between MG variables and sex, ocular discomfort symptoms, or meibum lipids classes. Conclusions: Progressive MG loss occurs normally with age accompanied by reduced quality and quantity of the meibum produced. However, clinical presentation of ocular discomfort symptoms is stalled without corresponding disruption to tear function.

To compare non-invasive break-up time (NIBUT) when measured with the Tearscope-Plus™ and the Oculus® Keratograph 5M, and to compare lipid layer thicknesses (LLT) when measured with the Tearscope-Plus™ and the LipiView®. This study also set out to establish the repeatability of these methods. The following measurements were taken from both eyes of 24 participants on two occasions: non-invasive keratograph break-up time using the Oculus® (NIKBUT-1 and NIKBUT-average), NIBUT using the Tearscope-Plus™, and LLT using the LipiView® (minimum, maximum, and average) and Tearscope-Plus™. The Tearscope-Plus™ grades were converted to nanometers. There were no significant differences between eyes (Tearscope-Plus™ NIBUT: p = 0.52; NIKBUT-1: p = 0.052; NIKBUT-average: p = 0.73; Tearscope-Plus™ LLT: p = 0.13; LipiView® average, maximum, or minimum: p = 0.68, 0.39 and 0.50, respectively) or days (Tearscope-Plus™ NIBUT: p = 0.32; NIKBUT-1: p = 0.65; NIKBUT-average: p = 0.54; Tearscope-Plus™ LLT: p = 0.26; LipiView® average, maximum, or minimum: p = 0.20, 0.09, and 0.10, respectively). LLT was significantly greater with the Tearscope-Plus™ (80.4 ± 34.0 nm) compared with the LipiView® average (56.3 ± 16.1 nm, p = 0.007), minimum (50.1 ± 15.8 nm, p < 0.001) but not maximum (67.2 ± 19.6 nm, p = 0.55). NIBUT was significantly greater with the Tearscope-Plus™ (15.9 ± 10.7 seconds) compared to the NIKBUT-1 (8.2 ± 3.5 seconds, p = 0.006) but not NIKBUT-average (10.9 ± 3.9 seconds, p = 0.08). The Tearscope-Plus™ is not interchangeable with either the Oculus® K5M measurement of tear stability (NIKBUT-1) or the LipiView® maximum and minimum lipid thickness.